



Oxford Genome Sciences Expands its Scientific Advisory Board

Senior Scientist with Experience at Amgen and Merck to Assist the Drive to Develop New Personalised Medicines

Oxford, UK, 5 March 2007. Oxford Genome Sciences (UK) Ltd "OGeS" announces today that it has further strengthened its Scientific Advisory Board (SAB) with the appointment of Dr Mike Gresser. Dr Gresser, who is currently Visiting Scholar at the Molecular Biology Institute at UCLA has significant pharmaceutical and academic experience which compliments the skills of the other members of the OGeS' SAB.

Prior to taking up his current position, Dr Gresser worked at Amgen Inc., Thousand Oaks, CA, USA, where he was for six years Vice President Research for Inflammation and for two years he also held the position of Head of Neuroscience Research. At Amgen, he worked on many molecular targets, introducing numerous small molecules, human antibodies, and other proteins into development. Before joining Amgen, Dr Gresser worked for 12 years at the Merck Frost Center for Therapeutic Research in Kirkland, Quebec where his final position was Executive Director of Biochemistry and Molecular Biology. While at Merck, Mike and his team worked on a variety of small molecule drug discovery programs, resulting in the introduction of numerous molecules into clinical trials, including Singulair and Vioxx.

Dr Gresser received his Ph.D. in Biochemistry in 1976 from Brandeis University, where his thesis research was done under the supervision of W.P. Jencks on the mechanism of ester aminolysis. He did postdoctoral studies at the Molecular Biology Institute at UCLA on the mitochondrial and chloroplast proton translocating adenosine triphosphate (ATP) synthases. He carried out this work under the supervision of Paul D. Boyer, who won the Nobel Prize in Chemistry in 1997 for his part in the elucidation of the enzymatic mechanism underlying the synthesis of ATP.

Dr Christian Rohlf, CEO of OGeS commenting on today's announcement said:

"I am delighted that Mike has agreed to join our Scientific Advisory Board. I am sure his close to twenty years of high level experience in the field of drug discovery will be extremely valuable to OGeS. With our recent deals with both Biosite and Medarex we are now well on our way to achieving our goal of developing personalised treatment regimes for patients with cancer. I have little doubt that with the wise counsel of Mike and the other members of our SAB, with their expertise in antibody therapies, diagnostics and cancer, will play an important role in us reaching this key corporate objective. I look forward to our forthcoming SAB meeting where we will be able to further develop OGeS plans to drive forward the development of our own pipeline of personalised medicines."

Dr Mike Gresser commented:

"I have been highly impressed with the progress that Oxford Genome Sciences has made in such a short time. I have little doubt that Christian and his team backed by the unique resources of the OGAP database will be able to play a major role in developing the personalised medicines that are clearly required to improve the treatment of major diseases such as cancer and Alzheimer's disease. I look forward to contributing to OGeS's exciting future and to working with my colleagues on the company's high quality SAB."

-Ends-



About Oxford Genome Sciences

Oxford Genome Sciences (OGeS) is focused on the development of personalised medicines, mainly for oncology indications and Alzheimer's disease. The company has developed a unique integrated platform that combines genomic, proteomic and clinical information to accelerate the discovery and validation of drug targets and biomarkers in human beings. OGeS believes the benefits are improved biomarkers for patient selection, drug response and efficacy monitoring, and the integration of diagnostics into drug development and product launch, thereby facilitating more accurate drug development and providing cost and time savings.

OGeS' strategy is to enter into flexible strategic alliances to capture maximum value from its unique and integrated platform for the development of new therapeutics and diagnostics in the field of cancer and Alzheimer's disease. The company has signed a number of collaborations in the area of colorectal cancer (CRC), which are together designed to achieve OGeS' objective of developing novel personalised solutions to the management of CRC. Specifically, OGeS has entered into partnerships with Medarex to discover, develop and commercialise new human antibody therapeutics for the treatment of cancers including CRC and with Biosite to develop a new diagnostic protein panel for relapsing CRC. In parallel, OGeS provides target and biomarker discovery and screening services to pharmaceutical and biotechnology companies providing OGeS with short-term revenues.

OGeS, a privately held company, was formed in 2004 and is based near Oxford, UK.

About OGAP[®]

Oxford Genome Anatomy Project (OGAP) holds one of the world's largest proprietary collection of proteins represented by the database, which contains over one million peptide sequences from 50 tissues and 60 disease states, mapped to approximately 15,000 genes and over eight million SNPs and haplotypes. The database can be customised for individual partners to support and enhance their preclinical and clinical drug development activities.

OGAP[®] is a registered trade mark of Oxford Genome Sciences (UK) Ltd.

For further information, please see www.oxfordgenomesciences.com

Contacts:

Oxford Genome Sciences

Dr Christian Rohlf, Chief Executive Officer
Tel: +44 (0)1235 861770
christian.rohlf@oxfordgenomesciences.com

Citigate Dewe Rogerson

David Dible, Valerie Auffray
Tel: +44 (0)207 638 9571
valerie.auffray@citigatedr.co.uk